Catalyst Biosciences Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and D...( SOUTH SAN FRANCISCO Calif. March 24 /...)

SOUTH SAN FRANCISCO, Calif., March 24 /PRNewswire/ -- Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase(TM) therapeutics, has appointed four new members to the company's Scientific Advisory Board (SAB). Robert J. Fletterick, Ph.D., David Ginsburg M.D., Guy S. Salvesen, Ph.D., and Gregory Stahl, Ph.D., join initial members Shaun Coughlin, M.D., Ph.D., Charles Craik, Ph.D., and James Wells, Ph.D.

"We are pleased to welcome this distinguished group of scientific leaders to the Catalyst Biosciences Scientific Advisory Board," said Dr. Craik, Chairman of the SAB and a founder of Catalyst Biosciences. "We believe that proteases have enormous potential as a broad class of therapeutics, and are excited by the opportunity to provide counsel to Catalyst as the company advances compounds generated from its drug discovery platform into clinical development."

"Our SAB includes world-renowned experts in a diverse group of fields, including proteases, protein engineering, structural biology, cellular enzymatic pathways, blood clotting and clotting disorders, inflammation, the complement system, and immunology," said Dr. Ed Madison, Chief Scientific Officer of Catalyst Biosciences. "We at Catalyst are fortunate to have access to such a wide variety of expertise, which will not only help us add capabilities to our protease drug discovery platform, but also promote our drug development efforts in areas such as hemophilia and related clotting disorders, and age-related macular degeneration and other complement-mediated diseases."

Professor Robert J. Fletterick, Ph.D. is in the Department of Biochemistry at the University of California, San Francisco (UCSF) where he has served as Chair and Vice Chair. He also holds a joint appointment with the Departments of Pharmaceutical Chemistry and Cellular and Molecular Pharmacology at UCSF. Professor Fletterick
'/>"/>